{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Treatment with Intravenous Alteplase for Acute Ischemic Stroke After Reversal of Dabigatran with Idarucizumab: A Case Study

Purpose of Activity

To present a case study in which idarucizumab was used to reverse dabigatran during an acute ischemic stroke.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Outline stroke pathology.
  2. Recall the risk of, assessment of, and symptoms of stroke.
  3. Identify treatment of stroke with idarucizumab and alteplase, for patients taking dabigatran.
Price: $12.95


  • ANCC 1.0 CH / 1.0 APH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.

Awarded Advanced Pharmacology Hours

Test Code: JNN0119
Published: Jan 2019
Expires: 12/4/2020
Passing Score: 13/18 (72%)
Authors: Sheila Jala,MHSS MCN; Elizabeth O'Brien, GradDipNeuroSci, MNNP